Resveratrol inhibits epithelial-mesenchymal transition in hepatocellular carcinoma

Bayoumi, Asmaa; Khalifa, Esraa; Sayed-Ahmed, Mohamed M.; Sharaky, Marwa; Nazmy, Maiiada H.

doi:10.21608/jabps.2023.233421.1201

Resveratrol inhibits epithelial-mesenchymal transition in hepatocellular carcinoma

Document Type : Review Articles

Authors

¹ Department of Biochemistry, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.

² Department of Biochemistry, Faculty of Pharmacy, Minia University, Minia 61519, Egypt

³ Pharmacology and Experimental Oncology Unit, National Cancer Institute, Cairo University, Cairo 11796, Egypt.

10.21608/jabps.2023.233421.1201

Abstract

Hepatocellular carcinoma (HCC) is a brutally aggressive cancer that puts a tremendous amount of strain on both the medical systems and the drug regulatory organizations as well. It is believed that a crucial stage in the development of HCC is the epithelial-mesenchymal transition (EMT), which increases hepatocyte malignancy and is linked to invasion and metastasis. Resveratrol (RES) has been shown to reverse EMT in a number of cancer types. In order to further understand how RES influences EMT in HCC, we have chosen to concentrate on studying and summarizing the serine/threonine kinase (Akt)/glycogen synthesis kinase 3-beta (GSK3β)/Snail signaling pathway as one of the central pathways involved in activating EMT and tumorigenesis in this review.

Keywords

Main Subjects